{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:18:10Z","timestamp":1773454690291,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-022-02337-y","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T14:06:45Z","timestamp":1653314805000},"page":"3387-3395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The negative impact of COVID-19 pandemic on age-related macular degeneration patients treated with intravitreal bevacizumab injections"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-8574","authenticated-orcid":false,"given":"Roee","family":"Arnon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Pikkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tal","family":"Yahalomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nir","family":"Stanescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keren","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari","family":"Leshno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asaf","family":"Achiron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assaf","family":"Hilely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"issue":"6","key":"2337_CR1","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00417-020-04703-x","volume":"258","author":"JF Korobelnik","year":"2020","unstructured":"Korobelnik JF, Loewenstein A, Eldem B et al (2020) Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. Graefe\u2019s Arch Clin Exp Ophthalmol 258(6):1149\u20131156. https:\/\/doi.org\/10.1007\/s00417-020-04703-x","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"2337_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s42399-020-00614-4","author":"LM Wasser","year":"2020","unstructured":"Wasser LM, Weill Y, Brosh K et al (2020) The impact of COVID-19 on intravitreal injection compliance. SN Compr Clin Med. https:\/\/doi.org\/10.1007\/s42399-020-00614-4","journal-title":"SN Compr Clin Med"},{"key":"2337_CR3","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.2147\/OPTH.S267427","volume":"14","author":"A Campos","year":"2020","unstructured":"Campos A, Oliveira N, Martins J et al (2020) The paradigm shift of ophthalmology in the COVID-19 era. Clin Ophthalmol 14:2625\u20132630. https:\/\/doi.org\/10.2147\/OPTH.S267427","journal-title":"Clin Ophthalmol"},{"issue":"14","key":"2337_CR4","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/nejmoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419\u20131431. https:\/\/doi.org\/10.1056\/nejmoa054481","journal-title":"N Engl J Med"},{"issue":"1","key":"2337_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ophtha.2007.03.008","volume":"115","author":"T Wong","year":"2008","unstructured":"Wong T, Chakravarthy U, Klein R et al (2008) The natural history and prognosis of neovascular age-related macular degeneration. A systematic review of the literature and meta-analysis. Ophthalmology 115(1):8. https:\/\/doi.org\/10.1016\/j.ophtha.2007.03.008","journal-title":"Ophthalmology"},{"key":"2337_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-020-04858-7","author":"E Borrelli","year":"2020","unstructured":"Borrelli E, Grosso D, Vella G et al (2020) Impact of COVID-19 on outpatient visits and intravitreal treatments in a referral retina unit: let\u2019s be ready for a plausible \u201crebound effect.\u201d Graefe\u2019s Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-020-04858-7","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"issue":"11","key":"2337_CR7","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120(11):2292\u20132299. https:\/\/doi.org\/10.1016\/j.ophtha.2013.03.046","journal-title":"Ophthalmology"},{"key":"2337_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.04.011","author":"P Abraham","year":"2010","unstructured":"Abraham P, Yue H, Wilson L (2010) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol. https:\/\/doi.org\/10.1016\/j.ajo.2010.04.011","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"2337_CR9","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","volume":"118","author":"U Schmidt-Erfurth","year":"2011","unstructured":"Schmidt-Erfurth U, Eldem B, Guymer R et al (2011) Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 118(5):831\u2013839. https:\/\/doi.org\/10.1016\/j.ophtha.2010.09.004","journal-title":"Ophthalmology"},{"issue":"3","key":"2337_CR10","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ophtha.2013.10.019","volume":"121","author":"E Daniel","year":"2014","unstructured":"Daniel E, Toth CA, Grunwald JE et al (2014) Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology 121(3):656\u2013666. https:\/\/doi.org\/10.1016\/j.ophtha.2013.10.019","journal-title":"Ophthalmology"},{"issue":"2","key":"2337_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jcrs.2004.01.014","volume":"30","author":"JT Holladay","year":"2004","unstructured":"Holladay JT (2004) Visual acuity measurements. J Cataract Refract Surg 30(2):287\u2013290. https:\/\/doi.org\/10.1016\/j.jcrs.2004.01.014","journal-title":"J Cataract Refract Surg"},{"key":"2337_CR12","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1136\/bmjophth-2020-000487","volume":"5","author":"K Safadi","year":"2020","unstructured":"Safadi K, Kruger JM, Chowers I et al (2020) Ophthalmology practice during the COVID-19 pandemic. BMJ Open Ophthalmol 5:487. https:\/\/doi.org\/10.1136\/bmjophth-2020-000487","journal-title":"BMJ Open Ophthalmol"},{"key":"2337_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF et al (2014) Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121:193\u2013201. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.011","journal-title":"Ophthalmology"},{"issue":"12","key":"2337_CR14","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","volume":"122","author":"CC Wykoff","year":"2015","unstructured":"Wykoff CC, Croft DE, Brown DM et al (2015) Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 122(12):2514\u20132522. https:\/\/doi.org\/10.1016\/j.ophtha.2015.08.009","journal-title":"Ophthalmology"},{"issue":"1","key":"2337_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/IAE.0000000000001923","volume":"39","author":"P Arendt","year":"2019","unstructured":"Arendt P, Yu S, Munk MR et al (2019) Exit strategy in a treat-and-extend regimen for exudative age-related macular degeneration. Retina 39(1):27\u201333. https:\/\/doi.org\/10.1097\/IAE.0000000000001923","journal-title":"Retina"},{"issue":"5","key":"2337_CR16","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","volume":"121","author":"A Tufail","year":"2014","unstructured":"Tufail A (2014) The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity manuscript no. 2013\u2013568. Ophthalmology 121(5):1092\u20131101. https:\/\/doi.org\/10.1016\/j.ophtha.2013.11.031","journal-title":"Ophthalmology"},{"issue":"11","key":"2337_CR17","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/JAMAOPHTHALMOL.2018.3578","volume":"136","author":"A Obeid","year":"2018","unstructured":"Obeid A, Gao X, Ali FS et al (2018) Loss to follow-up among patients with neovascular age-related macular degeneration who received intravitreal anti-vascular endothelial growth factor injections. JAMA Ophthalmol 136(11):1251\u20131259. https:\/\/doi.org\/10.1001\/JAMAOPHTHALMOL.2018.3578","journal-title":"JAMA Ophthalmol"},{"key":"2337_CR18","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.2147\/OPTH.S325763","volume":"15","author":"B Sobolewska","year":"2021","unstructured":"Sobolewska B, Sabsabi M, Ziemssen F (2021) Importance of treatment duration: unmasking barriers and discovering the reasons for undertreatment of anti-VEGF agents in neovascular age-related macular degeneration. Clin Ophthalmol 15:4317. https:\/\/doi.org\/10.2147\/OPTH.S325763","journal-title":"Clin Ophthalmol"},{"key":"2337_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/JCM10184087","author":"CA Rodr\u00edguez-Fern\u00e1ndez","year":"2021","unstructured":"Rodr\u00edguez-Fern\u00e1ndez CA, Varela-Agra M, P\u00e9rez-Rold\u00e1n L, \u00c1lvarez-Reguera A, Mart\u00ednez-Reglero C, Campo-Gesto A (2021) Impact of COVID-19 on eye care in Spain during the first phase of the pandemic. J Clin Med. https:\/\/doi.org\/10.3390\/JCM10184087","journal-title":"J Clin Med"},{"issue":"6","key":"2337_CR20","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.4103\/ijo.IJO_1391_20","volume":"68","author":"D Agarwal","year":"2020","unstructured":"Agarwal D, Kumar A (2020) Managing intravitreal injections in adults in COVID-19 and post-COVID-19 era\u2014initial experiences. Indian J Ophthalmol 68(6):1216\u20131218. https:\/\/doi.org\/10.4103\/ijo.IJO_1391_20","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"2337_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/bmjophth-2020-000560","volume":"5","author":"J Huemer","year":"2020","unstructured":"Huemer J, Hienert J, Hirn C et al (2020) Remodelling intravitreal therapy pathways for macular disease during the COVID-19 pandemic and an Austrian national lockdown. BMJ Open Ophthalmol 5(1):5. https:\/\/doi.org\/10.1136\/bmjophth-2020-000560","journal-title":"BMJ Open Ophthalmol"},{"issue":"1","key":"2337_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/1120672120962032","volume":"31","author":"A Carnevali","year":"2021","unstructured":"Carnevali A, Giannaccare G, Gatti V et al (2021) Intravitreal injections during COVID-19 outbreak: real-world experience from an Italian tertiary referral center. Eur J Ophthalmol 31(1):10\u201312. https:\/\/doi.org\/10.1177\/1120672120962032","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"2337_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","volume":"125","author":"R Silva","year":"2018","unstructured":"Silva R, Berta A, Larsen M et al (2018) Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology 125(1):57\u201365. https:\/\/doi.org\/10.1016\/j.ophtha.2017.07.014","journal-title":"Ophthalmology"},{"issue":"12","key":"2337_CR24","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1097\/IAE.0000000000001494","volume":"37","author":"JH Kim","year":"2017","unstructured":"Kim JH, Chang YS, Kim JW (2017) Natural course of patients discontinuing treatment for age-related macular degeneration and factors associated with visual prognosis. Retina 37(12):2254\u20132261. https:\/\/doi.org\/10.1097\/IAE.0000000000001494","journal-title":"Retina"},{"issue":"7","key":"2337_CR25","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1097\/IAE.0000000000000902","volume":"36","author":"SS Wickremasinghe","year":"2016","unstructured":"Wickremasinghe SS, Janakan V, Sandhu SS, Amirul-Islam FM, Abedi F, Guymer RH (2016) Implication of recurrent or retained fluid on optical coherence tomography for visual acuity during active treatment of neovascular age-related macular degeneration with a treat and extend protocol. Retina 36(7):1331\u20131339. https:\/\/doi.org\/10.1097\/IAE.0000000000000902","journal-title":"Retina"},{"issue":"12","key":"2337_CR26","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1016\/J.OPHTHA.2008.08.016","volume":"115","author":"PA Keane","year":"2008","unstructured":"Keane PA, Liakopoulos S, Chang KT et al (2008) Relationship between optical coherence tomography retinal parameters and visual acuity in neovascular age-related macular degeneration. Ophthalmology 115(12):2206\u20132214. https:\/\/doi.org\/10.1016\/J.OPHTHA.2008.08.016","journal-title":"Ophthalmology"},{"issue":"10","key":"2337_CR27","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1136\/BJOPHTHALMOL-2015-307375","volume":"100","author":"N Shah","year":"2016","unstructured":"Shah N, Dakin SC, Dobinson S, Tufail A, Egan CA, Anderson RS (2016) Visual acuity loss in patients with age-related macular degeneration measured using a novel high-pass letter chart. Br J Ophthalmol 100(10):1346\u20131352. https:\/\/doi.org\/10.1136\/BJOPHTHALMOL-2015-307375","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"2337_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000354551","volume":"231","author":"T Ristau","year":"2014","unstructured":"Ristau T, Keane PA, Walsh AC et al (2014) Relationship between visual acuity and spectral domain optical coherence tomography retinal parameters in neovascular age-related macular degeneration. Ophthalmologica 231(1):37\u201344. https:\/\/doi.org\/10.1159\/000354551","journal-title":"Ophthalmologica"},{"issue":"6","key":"2337_CR29","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/J.ORET.2017.10.003","volume":"2","author":"G Ying","year":"2018","unstructured":"Ying G, Maguire MG, Pan W et al (2018) Baseline predictors for five-year visual acuity outcomes in the comparison of AMD treatment trials. Ophthalmol Retina 2(6):525\u2013530. https:\/\/doi.org\/10.1016\/J.ORET.2017.10.003","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"2337_CR30","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/J.AJO.2015.07.034","volume":"160","author":"CD Regillo","year":"2015","unstructured":"Regillo CD, Busbee BG, Ho AC, Ding B, Haskova Z (2015) Baseline predictors of 12-month treatment response to ranibizumab in patients with wet age-related macular degeneration. Am J Ophthalmol 160(5):1014-1023.e2. https:\/\/doi.org\/10.1016\/J.AJO.2015.07.034","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"2337_CR31","doi-asserted-by":"publisher","first-page":"5040","DOI":"10.1167\/IOVS.15-16494","volume":"56","author":"B Chae","year":"2015","unstructured":"Chae B, Jung JJ, Mrejen S et al (2015) Baseline predictors for good versus poor visual outcomes in the treatment of neovascular age-related macular degeneration with intravitreal anti-VEGF therapy. Invest Ophthalmol Vis Sci 56(9):5040\u20135047. https:\/\/doi.org\/10.1167\/IOVS.15-16494","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2337_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/J.AJO.2018.10.022","volume":"198","author":"JM Seddon","year":"2019","unstructured":"Seddon JM, Rosner B (2019) Validated prediction models for macular degeneration progression and predictors of visual acuity loss identify high risk individuals. Am J Ophthalmol 198:223. https:\/\/doi.org\/10.1016\/J.AJO.2018.10.022","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"2337_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/EYE.2016.208","volume":"31","author":"M Gemenetzi","year":"2017","unstructured":"Gemenetzi M, Lotery AJ, Patel PJ (2017) Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents. Eye 31(1):1. https:\/\/doi.org\/10.1038\/EYE.2016.208","journal-title":"Eye"},{"issue":"5","key":"2337_CR34","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","volume":"126","author":"RH Guymer","year":"2019","unstructured":"Guymer RH, Markey CM, McAllister IL et al (2019) Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology 126(5):723\u2013734. https:\/\/doi.org\/10.1016\/j.ophtha.2018.11.025","journal-title":"Ophthalmology"},{"key":"2337_CR35","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","volume":"120","author":"GJ Jaffe","year":"2013","unstructured":"Jaffe GJ, Martin DF, Toth CA et al (2013) Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 120:1860\u20131870. https:\/\/doi.org\/10.1016\/j.ophtha.2013.01.073","journal-title":"Ophthalmology"},{"key":"2337_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/OPTH.S151611","volume":"12","author":"C Ehlken","year":"2018","unstructured":"Ehlken C, Helms M, B\u00f6hringer D et al (2018) Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol 12:13\u201320. https:\/\/doi.org\/10.2147\/OPTH.S151611","journal-title":"Clin Ophthalmol"},{"issue":"12","key":"2337_CR37","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s00417-020-04955-7","volume":"258","author":"E Borrelli","year":"2020","unstructured":"Borrelli E, Grosso D, Vella G et al (2020) Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic. Graefe\u2019s Arch Clin Exp Ophthalmol 258(12):2621\u20132628. https:\/\/doi.org\/10.1007\/s00417-020-04955-7","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"2337_CR38","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2147\/OPTH.S296345","volume":"15","author":"N Ashkenazy","year":"2021","unstructured":"Ashkenazy N, Goduni L, Smiddy WE (2021) Short-term effects of COVID-19-related deferral of intravitreal injection visits. Clin Ophthalmol 15:413\u2013417. https:\/\/doi.org\/10.2147\/OPTH.S296345","journal-title":"Clin Ophthalmol"},{"key":"2337_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S00417-021-05505-5","volume":"1","author":"J Hanhart","year":"2022","unstructured":"Hanhart J, Wiener R, Totah H et al (2022) Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration. Graefe\u2019s Arch Clin Exp Ophthalmol 1:1. https:\/\/doi.org\/10.1007\/S00417-021-05505-5","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"issue":"6","key":"2337_CR40","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","volume":"119","author":"MA Singer","year":"2012","unstructured":"Singer MA, Awh CC, Sadda S et al (2012) HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 119(6):1175\u20131183. https:\/\/doi.org\/10.1016\/j.ophtha.2011.12.016","journal-title":"Ophthalmology"},{"issue":"7","key":"2337_CR41","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119(7):1388\u20131398. https:\/\/doi.org\/10.1016\/j.ophtha.2012.03.053","journal-title":"Ophthalmology"},{"issue":"12","key":"2337_CR42","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119(12):2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"issue":"2","key":"2337_CR43","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2021","unstructured":"Okada M, Mitchell P, Finger RP et al (2021) Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology 128(2):234\u2013247. https:\/\/doi.org\/10.1016\/j.ophtha.2020.07.060","journal-title":"Ophthalmology"},{"issue":"8","key":"2337_CR44","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jfo.2017.03.005","volume":"40","author":"V Krivosic","year":"2017","unstructured":"Krivosic V, Philippakis E, Couturier A et al (2017) A \u201cfast track\u201d to improve management of neovascular age related macular degeneration. J Fr Ophtalmol 40(8):642\u2013647. https:\/\/doi.org\/10.1016\/j.jfo.2017.03.005","journal-title":"J Fr Ophtalmol"},{"issue":"8","key":"2337_CR45","doi-asserted-by":"publisher","first-page":"e649","DOI":"10.1111\/AOS.12735","volume":"93","author":"A Achiron","year":"2015","unstructured":"Achiron A, Lagstein O, Glick M, Gur Z, Bartov E, Burgansky-Eliash Z (2015) Quantifying metamorphopsia in patients with diabetic macular oedema. Acta Ophthalmol 93(8):e649\u2013e653. https:\/\/doi.org\/10.1111\/AOS.12735","journal-title":"Acta Ophthalmol"},{"issue":"12","key":"2337_CR46","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1055\/A-1271-6834","volume":"237","author":"K Nahen","year":"2020","unstructured":"Nahen K, Benyamini G, Loewenstein A (2020) Evaluation of a self-imaging SD-OCT system for remote monitoring of patients with neovascular age related macular degeneration. Klin Monbl Augenheilkd 237(12):1410\u20131418. https:\/\/doi.org\/10.1055\/A-1271-6834","journal-title":"Klin Monbl Augenheilkd"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-022-02337-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-022-02337-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-022-02337-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T18:11:09Z","timestamp":1666462269000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-022-02337-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":46,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["2337"],"URL":"https:\/\/doi.org\/10.1007\/s10792-022-02337-y","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]},"assertion":[{"value":"25 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study protocol was reviewed and approved by Assuta-Samson Hospital IRB, Approval Number 0117-20-AAA. The study has been granted an exemption from requiring written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}